{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-23-000015","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.068841+00:00","generated_at":"2026-06-20T00:24:41.138850+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer","bullets":["Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.","4-month progression-free survival rate of 77% and overall response rate of 22%; no drug-related discontinuations observed.","Compared to historical KEYNOTE-775 trial: ONA-XR+ANA showed higher 4-month PFS (77% vs 42% chemo, 67% Lenvima+Keytruda) and lower discontinuation (0% vs 8% and 33%).","Drug well-tolerated with mainly Grade 1-2 adverse events; updated data expected in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-23-000015","json":"https://secwatch.observer/filing/0001842952-23-000015.json","markdown":"https://secwatch.observer/filing/0001842952-23-000015.md","text":"https://secwatch.observer/filing/0001842952-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/0001842952-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000015/cntx-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:24:41.138850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}